The Medicare GLP-1 Bridge is a short-term demonstration run by the Centers for Medicare & Medicaid Services (CMS) that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027
GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro) work by slowing gastric emptying and activating receptors in the brainstem, which can trigger nausea and vomiting
Of them, two pioneered unimolecular agonists, tirzepatide (LY3298176) and peptide 20 (MAR423) have attracted significant attention from both academic and industrial communities (Fig
Research suggests that approximately 25% to 40% of weight loss during GLP-1 therapy may come from lean mass
These interactions might also control vessel permeability for nutrients in some segments of the blood circulation, since vessel wall integrity is known to by dependent on Src activation
Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of NOVOLOG therapy
